key: cord-0755189-7pln5iet
authors: Andina, D.; Belloni‐Fortina, A.; Bodemer, C.; Bonifazi, E.; Chiriac, A.; Colmenero, I.; Diociaiuti, A.; El‐Hachem, M.; Fertita, L.; van Gysel, D.; Hernández‐Martín, A.; Hubiche, T.; Luca, C.; Martos‐Cabrera, L.; Maruani, A.; Mazzotta, F.; Akkaya, A. D.; Casals, M.; Ferrando, J.; Grimalt, R.; Grozdev, I.; Kinsler, V.; Morren, M. A.; Munisami, M.; Nanda, A.; Novoa, M. P.; Ott, H.; Pasmans, S.; Salavastru, C.; Zawar, V.; Torrelo, A.
title: Skin manifestations of COVID‐19 in children: Part 3
date: 2020-11-18
journal: Clin Exp Dermatol
DOI: 10.1111/ced.14483
sha: 95ed46c59edb94dc9e54817122be59b90fb34191
doc_id: 755189
cord_uid: 7pln5iet

The current COVID‐19 pandemic is caused by the SARS‐CoV‐2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS‐CoV‐2 infection in children differ from those in adults as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID‐19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discuss one of the first and most widespread cutaneous manifestations of COVID‐19, chilblain‐like lesions, and in Part 2 we expanded to other manifestations, including erythema multiforme, urticaria and Kawasaki disease‐like inflammatory multisystemic syndrome. In this part of the review, we discuss the histological findings of COVID‐19 manifestations, and the testing and management of infected children for both COVID‐19 and any other pre‐existing conditions.

The current COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS-CoV-2 infection in children differ from those in adults as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID-19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discuss one of the first and most widespread cutaneous manifestations of COVID-19, chilblain-like lesions, and in Part 2 we expanded to other manifestations, including erythema multiforme, urticaria and Kawasaki disease-like inflammatory multisystemic syndrome. In this part of the review, we discuss the histological findings of COVID-19 manifestations, and the testing and management of infected children for both COVID-19 and any other pre-existing conditions.

The current COVID-19 pandemic has affected almost all countries worldwide. The overall clinical presentation, course and outcome of SARS-CoV-2 infection, as well as the cutaneous manifestations of childhood COVID-19 differ from those of adults. Below we describe the histological findings of COVID-19 manifestations, and the testing and management of infected children.

A systematic review found that skin lesions were present in only 0.25% of 2445 pediatric patients in 119 published studies. 1 In addition, biopsies from skin lesions in children with confirmed or suspected COVID-19 have rarely been described in the literature. Most of the histopathological descriptions come from isolated cases or small series, and some lesion types have been biopsied only in adults. As cutaneous lesions may be related to the direct effect of the virus and/or to the immune responses secondary to the infection, histological findings may reflect the direct cytopathic effect of the virus or secondary inflammatory responses. Histology often follows usual patterns (Table 1) .

To our knowledge, no reports on histological features of urticarial rashes in children have been published. Histology in adults reveal perivascular infiltrates of lymphocytes, eosinophils and upper dermal oedema, 2 and vacuolar-type interface dermatitis with occasional necrotic keratinocytes without the presence of eosinophils, resembling erythema multiforme (EM). 3

Biopsies from vesicular lesions in adults with COVID-19 have shown suprabasal intraepidermal unilocular vesicles with prominent nonballooning acantholysis and eosinophilic dyskeratosis, with a striking 'pomegranate-like' aspect. No nuclear atypia or large multinucleated cells were noted, and no vasculitis was seen. Direct immunofluorescence and SARS-CoV-2 PCR tests performed on vesicles were reported to be negative. 4 The findings described can mimic other acantholytic disorders such as autoimmune or familial pemphigus or Grover transient acantholytic dermatosis 5 and it is important to exclude herpetic infection. 6, 7 Purpuric and livedoid lesions In a case series of adult patients with COVID-19 and purpuric skin lesions, a pauci-inflammatory thrombogenic vasculopathy, with deposition of C5b-9 and C4d and colocalization of COVID-19 spike glycoproteins and C5b-9 and C4d in the cutaneous microvasculature was demonstrated. 8, 9 Pityriasis rosea-like lesions

The histology of a digitate papulosquamous eruption reminiscent of pityriasis rosea in an adult patient revealed mild diffuse epidermal spongiosis, along with spongiotic vesicles containing lymphocytes and Langerhans cells. The papillary dermis was slightly oedematous, and a mild lymphohistiocytic infiltrate was seen in the upper dermis. 10

There is currently no test with high sensitivity and specificity for diagnosing COVID-19 featuring skin lesions in the paediatric population. Therefore, the epidemiological context, possibility of exposure to COVID-19, history of flu signs and the characteristics of cutaneous signs (acute signs, but these are not very specific) are key points that allow for a tentative diagnosis of COVID-19-related skin lesions in children.

Data published by the Chinese Epidemiology Group of Emergency Response Mechanism of New Coronavirus Pneumonia showed that about 2% of the patients infected with COVID-19 or SARS-CoV-2 (out of 72 314 patients) were children aged 0-9 years. 11 The incubation period in children is usually about 2 days, with a range of 2-10 days. Children usually undergo more asymptomatic forms, less severe symptoms and better prognosis than adults. [11] [12] [13] Because > 90% of the children have asymptomatic, mild or moderate disease, the diagnosis of COVID-19 may be overlooked. However, it may be necessary to better characterize the cases of COVID-19 in children to allow better control of the pandemic.

Some indications for the proper testing and diagnosis of children with suspected COVID-19 are provided, along with an algorithm (Fig. 1 ) that can help clinicians to investigate children with skin rashes suspected of COVID-19 infection.

The gold standard for confirmation of COVID-19 in subjects with clinical symptoms consists of testing samples taken from the respiratory tract to assess for ª 2020 British Association of Dermatologists the presence of nucleic acid targets specific to SARS-CoV-2. Nasopharyngeal swabs are the preferred choice for testing, although oropharyngeal swabs are also acceptable. 13 Reverse transcription (RT)-PCR was shown to be very specific, but varied in sensitivity, thus negative results do exclude the possibility of infection. RT-PCR results vary over time, and testing is more likely to be positive if performed during the first days of symptoms. 14 RT-PCR testing was reported in children presenting with COVID-19-related cutaneous signs, such as chilblains (Fig. 2) . [15] [16] [17] [18] [19] [20] [21] Of these, 68 had pseudo-chilblains, 4 had EM, and 1 was a neonate with diffuse livedo associated with acute respiratory signs. Of the 69 patients, 61 underwent nasopharyngeal or oropharyngeal swabs for RT-PCR testing, and 59 (97%) of these were negative. The two positive cases included a neonate with livedo, 21 and a child with chilblains and associated EM who had gastrointestinal signs 2 days before occurrence of the chilblains. 18 The published data suggest that when skin manifestations are concomitant with general signs of viral infection, PCR might be positive and is thus recommended (however, sensitivity is low), whereas when signs appear several days later, as is the case with pseudo-chilblains, testing is usually negative. Various serological assays, such as ELISA to determine antibodies against COVID-19 are currently available, and provide information about the development of immunity against reinfection. With the available data, the utility of serological assays for diagnosing acute COVID-19 infection seems limited. It has been shown that seroconversion occurs with a median time of 5-12 days for IgM antibodies and after 14 days for IgG and IgA. 14, 23 Crossreactivity is also a potential problem, 24 and a crossreactive antibody response between SARS-CoV-2 and SARS-CoV infection has been shown. 25 Interestingly, SARS-CoV-2 CD4 + cells are detected in 40%-60% of unexposed individuals. This result suggests that crossreactive T-cell recognition might exist between previous common cold coronavirus infection and SARS-CoV-2. 26 There are very limited data on use of serological assays in children with cutaneous COVID manifestations, but when performed they were negative for IgG and IgM in all cases. 17, 19, 21 Only one patient showed positive IgA against COVID-19. 19 In an Italian series, specific serology testing against the S1 domain of SARS-Cov-2 spike protein was positive in 6 of 19 cases for IgA, and in 1 of 19 for IgG. 17 The relevance of serological assay in dermatological conditions needs to be confirmed. 27 The published data suggest that the presence of IgM and IgG by immunoassays has very low diagnostic relevance to cutaneous signs of COVID-19 in children. The observations related to presence of IgA antibody responses need to be investigated further.

Laboratory tests are necessary in patients with severe general symptoms of COVID-19 and in cases of cytokine storm syndrome, and such patients may require hospitalization. This is usually not the case for patients with isolated skin lesions except when such lesions are associated with general symptoms or persist beyond the expected duration. Unwell patients may demonstrate decreased albumin (~75%), elevated C-reactive protein (~60%) and elevated lactate dehydrogenase (~60%) levels and lymphopenia (~40%). There is currently no biomarker or combination of biomarkers that is sufficiently sensitive/specific to establish a diagnosis of COVID-19, or to pragmatically predict its clinical course. 13 In most reported children with common COVID-19related skin lesions who underwent routine laboratory tests, no significant abnormalities in serum chemistry were observed. The various coagulation markers were observed to be within the normal range in children, except for D-dimer levels, which were slightly raised in three cases, whereas most others had a value of < 1000 ng/mL (normal level < 500 ng/mL). 15, 16, 19 Adult patients with acral cyanosis often have a hypercoagulable and disseminated intravascular coagulation. 28 In children with the severe disease of paediatric inflammatory multisystem syndrome (PIMS), abnormalities in laboratory values have been extensively reported.

Markers of autoimmunity, including antinuclear antibodies and cryoglobulins, tested in 14 of the 69 published cases of COVID-19 in children, showed no significant anomalies, except in one child with COVID-19-related chilblains, who had raised anticardiolipin IgG antibodies. 19 

Interference of COVID-19 with treatment of chronic skin diseases in children During the COVID-19 pandemic, follow-up for children affected by chronic diseases has been interrupted or moved to remote methods, especially in heavily affected countries. Outdoor play, activities and even schooling in most cases has been interrupted.

A study to evaluate the influence of COVID-19 on hospitalizations in a tertiary dermatology department in southwest Poland compared the number of hospitalized patients during the COVID-19 pandemic with the same period in 2019. 29 The number of hospitalized children (2-18 years old) decreased from 81 (12.9%) in 2019 to 12 (6.8%) during the pandemic, especially for patients with chronic inflammatory diseases [atopic dermatitis (AD), lichen planus, eczema, psoriasis, urticaria and pityriasis rubra pilaris]. 29 Similar data have been reported from Italy. 30, 31 One study described the management of 6890 patients with psoriasis, including 120 children, during the pandemic in the three major reference centres for psoriasis in Sardinia, Italy; about 23% of the patients had severe psoriasis. The Italian drug agency (Agenzia Italiana del Farmaco) declared an automatic renewal of the therapeutic plan of patients with rare diseases or those under treatment with biologics. However, the dermatologists found difficulties including limitations to faceto-face consultations for severe cases, high infection rate among dermatologists (40% compared with the national average of 7%-8%), and cancellation of outpatient clinics. 31 Dermatological consultations in Konya (Turkey) during the pandemic were mainly carried out by teledermatology (72.8% of consultations), which was reported to reduce the risk of disease transmission. 32 A task force of 37 expert paediatric dermatologists completed a survey concerning the management of systemic immunosuppressive therapies for children during SARS-CoV-2 infection spread and developed educational contents for patients, caregivers and providers accessible online. 33 Three main areas were analysed: (i) initiation of treatment, (ii) continuation of treatment and (iii) laboratory monitoring of systemic therapies. COVID-19 significantly affected the management of immunosuppressive medications (97% of the respondents), depending on the drug (87%), the condition being treated (78%), family/patient preferences (62%) and risks of COVID-19 vs. not treating the skin disease (84%). The management of specific immunosuppressive medications was analysed based on various clinical circumstances: (i) asymptomatic patients, (ii) patients with upper respiratory tract infection (URI) with unknown COVID-19 status, (iii) patients with confirmed exposure to COVID-19, and (iv) patients with confirmed SARS-CoV-2 infection. Selected drugs were classified into systemic therapy (methotrexate, mycophenolate mofetil, azathioprine, ciclosporin, systemic steroids, apremilast, JAK inhibitors) and biologic therapies [anti-tumour necrosis factor-a, anti-interleukin (IL)-17, anti-IL-12/23, anti-IL-23 and dupilumab].

The majority of dermatologists agreed that for SARS-CoV-2-negative patients, all treatment should be continued or adapted to the context. 33 In patients with a URI, most drugs were temporarily discontinued, except for systemic steroids, which were often decreased in dosage (30% of respondents), while ª 2020 British Association of Dermatologists apremilast and dupilumab were mostly continued (46% and 68%, respectively). In patients exposed to confirmed households and with confirmed COVID-19 infection, all the selected drugs were mostly discontinued or decreased in dose, including systemic steroids (24% and 19% of respondents, respectively), apremilast (30% and 24%, respectively) and dupilumab (49% and 16%, respectively). In addition, the frequency of laboratory monitoring was also reduced. Notably, discontinuance of a biologic therapy could lead to failure after reintroduction, and tapering of corticosteroids may need to be assessed with regard to adrenal suppression, especially in cases of infection when stressdose steroids may be required. In summary, a final statement for the management of immunosuppressive medications was not achieved, and it was advised that decisions regarding treatment were regularly discussed with the patients and their caregivers. 33 

The European Task Force on Atopic Dermatitis (ETFAD) published a statement on SARS-CoV-2 and AD. 34 ETFAD suggested advising patients to continue all ongoing medications to prevent the disease worsening, to observe hygienic procedures and to moisturize their skin regularly. In addition, if systemic treatment should be stopped, it should be replaced by a topical therapy. Dupilumab is preferred over other medications, because it does not increase the risk of viral infection.

Another evaluation of the use of systemic drugs during the COVID outbreak suggested that dupilumab, apremilast and acitretin are not associated with increased risk of infection and seem to be safe during the COVID-19 pandemic. 35 Other suggestions to optimize the care of patients with AD during the outbreak included encouraging good skin care (e.g. hygiene, moisturizing), providing access to telehealth and following published indications on systemic drugs in this setting. 36 Immunosuppressive medications Similar advice has been advocated for the use of immunosuppressive medications in psoriasis, autoimmune bullous diseases and AD. [37] [38] [39] [40] Treatment of autoimmune bullous diseases should be maintained, owing to the high rate of morbidity and mortality of this disease group. 41 In patients infected with SARS-CoV-2, azathioprine, mycophenolate mofetil/sodium, cyclophosphamide, methotrexate and ciclosporin may be stopped, whereas topical corticosteroids, dapsone/ sulfapyridine, low-dose prednisone/prednisolone, doxycycline/tetracycline, colchicine and intravenous immunoglobulin can be continued. Systemic corticosteroids should be tapered, not suddenly interrupted. Regular updated through World Health Organization (WHO)/Centers for Disease Control homepage and the European Academy of Dermatology and Venereology, which has published specific recommendations on its website, are recommended. 41 The COVID-19 pandemic has had psychosocial impacts on healthcare providers and patients with chronic skin disorders. 42 Additionally, quarantine may have negative effects on chronic inflammatory conditions. Immobilization, decrease in physical activity and lockdown induce higher caloric intake, obesity and a negative impact on mood. All these factors worsen conditions such as psoriasis and hidradenitis suppurativa, and decrease adherence to treatment. 43 Remote medicine and use of dermoscopy Teledermatology and telemedicine offer an opportunity for continuing healthcare delivery. [44] [45] [46] Some suggestions on using dermoscopy during the COVID-19 pandemic have been proposed: (i) avoid dermoscopy at specific body sites: mucosa, hands, nails, face and eyes; (ii) patient and doctors should respect distancing in the waiting room, wear masks, and wash or sanitize hands before and after the examination; (iii) the dermoscope should sanitized before and after each patient; (iv) the examined skin should also be sanitized before and after the examination; and (v) digital reports should be encouraged in preference to printed reports. 47 Recommendations for paediatric dermatologists attending children with suspected COVID-19 skin disease

The following advice may continue to change over the following months. Only 1%-5% of confirmed COVID-19-positive cases are children. Overall, children have milder disease, and deaths in children are exceptional. 48 As for adults, the initial evaluation of children should be carried out in the department at which the patient is first attended (e.g. emergency room, inpatient room), to avoid unnecessary patient movement in the hospital and avoid contact with patients in waiting areas. Dermatologists attending children with skin lesions who are suspected of having COVID-19 should wear proper personal protective equipment, which may include mask, goggles, protective suits, head coverings and gloves. 49 A thorough evaluation by an experienced paediatrician is highly recommended. Most children with SARS-CoV-2 infection should have a good general status and normal vital signs; poor general status and tachycardia are early signs of shock in COVID-19. 50, 51 Severe gastrointestinal symptoms appear to be more frequent than respiratory symptoms in severely ill children, and can indicate the possibility of PIMS. 51 However, most patients with cutaneous lesions do not present with systemic symptoms or, if present, these are mild, and usually occur days to weeks before the appearance of the skin lesions. 16 If history and clinical examination suggest SARS-CoV-2 infection, it is recommended to test by PCR and to follow up household contacts according to local health authority protocols. In children with mild symptoms, the likelihood of transmission of the infection beyond the first week after the onset of symptoms is very low, 52,53 so home lockdown for 10 days is recommended. If an infectious child requires consultation, then the healthcare practitioner should try to see them in a COVID-19 area, as late as possible during the day to allow cleaning, and caregivers with symptoms must not attend. Informative announcements in the dermatology clinics must clearly explain medical requirements, such as fever screening at the clinic entrance, questionnaires about presence of symptoms in the previous 2 weeks or close contact with suspected or confirmed COVID-19 cases, use of alcoholbased hand sanitizer, wearing of surgical masks by children and caregivers, and maintaining appropriate distancing. Proper cleaning and disinfecting of the room should be carried out after every suspected or confirmed child is attended. Surfaces should be cleaned and disinfected regularly, such as doorknobs, light switches, computer keyboards, phones and examination tools such as dermoscopes. 54 Surfaces should be disinfected with 1% sodium hypochlorite solutions, and electronic gadgets with the alcohol-based disinfectant.

After an initial in-person evaluation, teledermatology is a good choice for follow-up of children with COVID-19 until the skin lesions are completely resolved. 55 All health professionals involved in the care of children should try to stay updated, in spite of the increasing number of articles appearing in the literature. Up until the 11 June 2020, only 3 months after the WHO declared the pandemic, 38 903 articles about COVID-19 had been published in PubMed, with 1502 of these related to the paediatric population.

• The histopathology of COVID-19-related chilblains is similar to that of classic primary chilblains.

• Sensitivity and specificity of PCR and serology tests are not high in children, and epidemiological data are important in the diagnosis of COVID-19 in children.

• More than 90% of children have asymptomatic, mild or moderate COVID-19, and the diagnosis may thus be overlooked. • COVID-19 may interfere with the course of chronic skin diseases and with the access of patients to specialized care; teledermatology may partly overcome this latter problem. • COVID-19 may interfere with the use of immunosuppressive drugs for skin diseases; the continuation of these drugs should be balanced with the risk of withdrawal and worsening of the skin condition. • Dupilumab appears to be safe and not associated with increased risk of infection.

COVID-19 in 7780 pediatric patients: a systematic review

Urticaria-like lesions in COVID-19 patients are not really urticaria -a case with clinicopathologic correlation

Clinical and histopathological features and potential pathological mechanisms of skin lesions in COVID-19: review of the literature

Histology of skin lesions establishes that the vesicular rash associated with COVID-19 is not 'varicella-like

Clinical and histological characterization of vesicular COVID-19 rashes: a prospective study in a tertiary care hospital": pseudoherpetic Grover disease seems to appear in patients with COVID-19 infection

Herpes zoster might be an indicator for latent COVID 19 infection

Herpes zoster (shingles) complicating the course of COVID19 infection

AGRO, complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases

Retiform purpura as a dermatological sign of covid-19 coagulopathy

Digitate papulosquamous eruption associated with severe acute respiratory syndrome coronavirus 2 infection

The epidemiological characteristics of an outbreak of novel coronavirus diseases (COVID-19) in China] (in Chinese)

Association between a novel human coronavirus and Kawasaki disease

Interim guidelines for collecting, handling, and testing clinical specimens from persons for coronavirus disease 2019 (COVID-19)

Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults

Interpreting diagnostic tests for SARS-CoV-2

Chilblain-like lesions in children following suspected COVID-19 infection

Chilblains in children in the setting of COVID-19 pandemic

A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19 infection

Erythema multiforme-like lesions in children and COVID-19

Chilblains appear as a manifestation of SARS-CoV-2 infection and reveal features of type I interferonopathy and microvasculopathy

Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report

Clustered cases of acral perniosis: clinical features, histopathology and relationship to COVID-19

Precautions are needed for COVID-19 patients with coinfection of common respiratory pathogens

Virological assessment of hospitalized patients with COVID-19

An outbreak of human coronavirus OC43 infection and serological cross-reactivity with SARS coronavirus

Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples

COVID-19 and its implications for thrombosis and anticoagulation

Influence of COVID-19 pandemic on hospitalizations at the tertiary dermatology department in south-west Poland

The COVID-19 outbreak in Italy: preventive and protective measures adopted by the Dermatology Unit of Bologna University Hospital

Psoriasis health care in the time of the coronavirus pandemic: insights from dedicated centers in Sardinia (Italy)

Evaluation of dermatology consultations in the era of COVID-19

Systemic immunosuppressive therapy for inflammatory skin diseases in children: expert consensus-based guidance for clinical decision-making during the COVID-19 pandemic

European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis

Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic

Optimizing care for atopic dermatitis patients during COVID-19 pandemic

Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic

Management of pemphigus in COVID-19 pandemic era; a review article

Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?

COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: an Australian/New Zealand consensus statement

Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic

Mass quarantine measures in the time of COVID-19 pandemic: psychosocial implications for chronic skin conditions and a call for qualitative studies

COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions?

Management strategies of autoimmune bullous diseases during the outbreak of novel coronavirus disease (COVID-19)

Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during Covid-19 emergency in a tertiary center in Italy

How can I take care of you? The dermatologist meets patients' needs during the Covid19 pandemic

Art of performing dermoscopy during the times of coronavirus disease (COVID-19): simple change in approach can save the day!

Infection control practices in children during COVID-19 pandemic: differences from adults

What are we doing in the dermatology outpatient department amidst the raging of the 2019 novel coronavirus?

Hyperinflammatory shock in children during COVID-19 pandemic

Severe SARS-CoV-2 infection in children with suspected acute abdomen: a case series from a tertiary hospital in Spain

Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset

Viral dynamics in mild and severe cases of COVID-19

COVID-19 and dermatology: a comprehensive guide for dermatologists

Teledermatology: a useful tool to fight COVID-19

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

SARS-COV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of 7 paediatric patients

Skin manifestations of COVID-19

Suspected COVID-19-related reticulated purpura of the soles in an infant

To gain up-to-date knowledge on the histological features of COVID-19-related skin diseases and the treatments for other skin diseases during the pandemic. 

This learning activity is freely available online at http://www.wileyhealthlearning.com/ced Users are encouraged to • Read the article in print or online, paying particular attention to the learning points and any author conflict of interest disclosures. • Reflect on the article. • Register or login online at http://www.wileyhealth learning.com/ced and answer the CPD questions. • Complete the required evaluation component of the activity.Once the test is passed, you will receive a certificate and the learning activity can be added to your RCP CPD diary as a self-certified entry. This activity will be available for CPD credit for 2 years following its publication date. At that time, it will be reviewed and potentially updated and extended for an additional period.